If the risk of mass delistings is as real as some claim, with the obvious implications for patients, then surely it needs to be part of any forum hosted by or even involving the industry?
Surely the best 'patient view' is one that is fully informed?
September 2, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 6 February
February 6, 2026 - - Podcast -
AI in healthcare and why doing nothing might be the biggest risk
February 5, 2026 - - Latest News -
An effective example of making the case for reform in a status quo-biased system
February 5, 2026 - - Latest News -
Pharmac consults on expanding access to Takeda blood cancer therapy
February 5, 2026 - - Latest News -
GBMA moves to reclaim the reform agenda with a focus on pricing and supply
February 5, 2026 - - Latest News -
Nuclear medicine sector argues for dedicated scheme to unlock cancer therapies
February 4, 2026 - - Latest News -
Pfizer’s once-monthly weight-loss injection delivers strong mid-stage results
February 4, 2026 - - Latest News

